TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04200313

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas (BP) with Aspart or Lispro
Description: iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas (BP) with Aspart or Lispro
Description: iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor using lispro or aspart insulin.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas with Fiasp (BPFiasp)
Description: iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas with Fiasp (BPFiasp)
Description: iLet Bionic Pancreas System, which consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls Fiasp insulin delivery based on glucose values obtained by communicating with a Dexcom G6 sensor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Description: Using pre-study insulin regimen with the Dexcom G6 CGM

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: Using pre-study insulin regimen with the Dexcom G6 CGM

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care (UC)
Description: Using pre-study insulin regimen with the Dexcom G6 CGM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BP Guidance Insulin Dosing
Description: Pre-study insulin delivery method with SMBG and blinded CGM with dosing guidance by the BP
Study: NCT00932334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TALK PLUS
Description: Participants receive and educational video and booklet about living kidney donation and meet with a social worker

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TALK Standard
Description: Participants receive and educational video and booklet about living kidney donation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: Participants receive their usual care
Study: NCT04581473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT041 autologous CAR T-cell injection
Description: Up to 3 times CT041 autologous CAR T-cell injection infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）
Description: Physician's choice of any BSC listed above
Study: NCT02693301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Study: NCT00218803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse asthma education intervention
Description: Asthma Education

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control Group
Description: Asthma Education
Study: NCT03218696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Syrup for adults and children
Description: The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
Study: NCT00941564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula milk based
Description: Consume ad lib

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula milk based
Description: consume ad lib
Study: NCT03152045

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
Study: NCT03987230

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sensitive Eyes® Plus Saline Solution
Description: Sensitive Eyes® Plus Saline Solution

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oust™ Demodex® Wipes™
Description: Oust™ Demodex® Wipes™

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-LID N LASH PLUS® Eyelid Cleanser
Description: I-LID N LASH PLUS® Eyelid Cleanser

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephadex Lid Wipes
Description: Blephadex Lid Wipes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eye Cleanse Lid Wipes
Description: Eye Cleanse Lid Wipes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephademodex
Description: Blephademodex
Study: NCT03004313

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pet Scan
Description: Subjects will undergo Pet Scanning for 90 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pet Scan
Description: Subjects will undergo Pet Scanning for 90 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Testing (QST)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST)
Study: NCT02762734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEDIA
Description: The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent.
Study: NCT04496141

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibody immunoassays
Description: Different commercial SARS-CoV-2 antibody immunoassays

Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 antibody immunoassays
Description: Different commercial SARS-CoV-2 antibody immunoassays
Study: NCT02443506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 623
Description: Single dose of AMG 623 administered as subcutaneous and intravenous doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
Study: NCT03150524

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCD- cerebral blood flow velocities
Description: Participants will undergo daily TCD for monitoring of cerebral blood flow.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCD- cerebral blood flow velocities
Description: Participants will undergo daily TCD for monitoring of cerebral blood flow.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache pain score
Description: Participants will be evaluated by nurses for headache frequency and severity every shift.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache pain score
Description: Participants will be evaluated by nurses for headache frequency and severity every shift.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurological examination
Description: Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurological examination
Description: Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Repeat Neuroimaging
Description: All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Repeat Neuroimaging
Description: All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimodipine
Description: Participants will be administered nimodipine every 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil ER
Description: Participants will be administered long acting verapamil every 12 hours.
Study: NCT02671318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug conversion to sirolimus
Description: Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of the current regimen
Description: Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
Study: NCT03219255

Intervention type: DRUG
Intervention: RELVAR 100 ELLIPTA
Description: RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
Study: NCT02450123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Study: NCT01178281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 0.5 mg
Description: Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator to active drug; Placebo capsule taken by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 0.5 mg capsule taken by mouth once daily.
Study: NCT02895698

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dry cupping
Description: Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
Study: NCT04401761

Intervention type: DRUG
Intervention: Rivaroxaban (BAY59-7939, Xarelto)
Description: 2.5 mg twice daily
Study: NCT02895698

Intervention type: OTHER
Group type: OTHER
Intervention: Stretching exercises
Description: * The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.~* Standing self-stretching of the calf muscles.~* Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.~* All stretches were done six times and the duration of each stretch is 30 seconds.
Study: NCT03220659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-point pacing
Description: Pacing from more than one pole from the left ventricular lead

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard settings
Description: Normal bipolar LV pacing
Study: NCT04225637

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrew-Supported Maxillary Expander- Slow activation
Description: A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated slowly by turning the expansion screw once every other day to correct the transverse maxillary deficiency.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrew-Supported Maxillary Expander- Rapid activation
Description: A maxillary expander is supported on 4 palatal miniscrews. The appliance is activated rapidly by turning the expansion screw twice per day to correct the transverse maxillary deficiency.
Study: NCT01265589

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: surfactant
Description: Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
Study: NCT04401761

Intervention type: DRUG
Intervention: Acetylsalicylic acid
Description: 75 - 100 mg once daily at the discretion of the investigator
Study: NCT04482075

Intervention type: OTHER
Group type: OTHER
Intervention: segmental stability training
Description: SEGMENTAL STABILISATION TRAINING (SST): This part of the therapy shall involve Isometric co-contraction of Lumbar Transversus abdominis and Lumbar Multifidus. The patient shall perform 10 repetitions of abdominal drawing-in manoeuvre with 30-40% Maximal Voluntary Contraction (MVC) with a 10-second hold in specific prescribed positions.
Study: NCT00831298

Intervention type: OTHER
Group type: OTHER
Intervention: Analysis of sleep disturbance
Description: Behavioral Questionnaire Sleep Recordings Genetic analysis
Study: NCT04265638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: One on one exercise with a cancer exercise specialist 1 hour 3 times a week for 12 weeks.
Study: NCT01265589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: surfactant+vitamin A
Description: Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
Study: NCT01550835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)
Description: Standard of care use of an embolic protection device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)
Description: Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
Study: NCT01254890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
Study: NCT03457272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New risk assessment
Description: Consists of a simple physiological scoring system and an assessment of patients who should assist healthcare professionals in identifying patients at risk of clinical deterioration earlier and support timely response and escalation of observation, care and treatment and thereby prevent the development of severe clinical deterioration.~The patients included in the study will be monitored using the new risk assessment tool with different intervals according to the patients' conditions. Underlying the tool are algorithms of action for intervention in the critically ill patient, inter professional guidelines and guidance for standardized monitoring, escalation plans and huddles.
Study: NCT04140825

Intervention type: DEVICE
Intervention: Resmon PRO FULL
Description: Measurement of lung impedance by the Forced Oscillation Technique
Study: NCT00295438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-Based Tele-Echography (TER)
Description: Robot-Based Tele-Echography, ultrasound performed by the radiologist

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-Based Tele-Echography (TER)
Description: Robot-Based Tele-Echography, ultrasound performed by the radiologist
Study: NCT03784625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 1)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 800 MBq/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 2)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 1600 MBq/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 3)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 2700 MBq/m²

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [131I]ICF01012 (therapeutic dose level 4)
Description: * 1 diagnostic injection (D0) at a diagnostic dose of 185 MBq. This first dose permits to pre-select patients who will received a therapeutic dose according to the dosimetry results ( binding on at least a tumoral lesion, and an acceptable radiation absorbed dose to major organs)~* 1 therapeutic injection (D11) at a dose of 4000 MBq/m²
Study: NCT00295438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound method FAST
Description: FAST,ultrasound performed by the emergency doctor

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound method FAST
Description: FAST,ultrasound performed by the emergency doctor
Study: NCT04218773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Patients will receive intravenous phenylephrine at a rate of 60 µg/min. The infusion rate will be adjusted at 30 µg/min increments (maximum 180 µg/min) at 3-minute intervals to maintain an increase in SBP to the target SBP of 160 - 220 mmHg or a 20% increase above baseline SBP values.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: As an alternative to intravenous phenylephrine, intravenous norepinephrine can be used with an initial infusion rate of 3 mcg/min. The initial infusion rate of norepinephrine will be adjusted at 1 mcg/min increments at 3-minute intervals to achieve and maintain the target blood pressure. Maximum dose is 25 mcg/min. Combination therapy with both agents (phenylephrine and norepinephrine) to achieve and maintain blood pressure targets is not permitted.
Study: NCT01688960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Description: Dose level 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept)
Description: Dose level 2
Study: NCT01809041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Study: NCT01759615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Enteral feeding
Description: Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late enteral feeding
Description: Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
Study: NCT03075956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg E4 single-dose
Description: A single oral dose of 5 mg E4 will be administered during Period 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4 single-dose
Description: A single oral dose of 15 mg E4 will be administered during Period 1 of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45 mg E4 single-dose
Description: A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15 mg E4 multiple-dose
Description: 15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study